acute ischemic stroke
Conditions
Interventions
Group A:Saline+Tirofiban
groupB:Aspirin +Clopidogrel or oral anticoagulant
Sponsors
The Affiliated Weihai Central Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: 1) Aged >= 18 years; 2) Sudden onset of acute ischemic stroke with symptom onset or wake-up stroke (the starting point of sleep) to random treatment (OTT): 4.5 hours = 6 points; 6)NIHSS>6, Perfusion lesion–ischemic core mismatch was defined as a ratio < 1.2 between the volume of hypoperfusion and the volume of the ischemic core, an absolute difference in volume greater than 10 ml, and an ischemic-core volume of less than 70 ml on CTP; 7) Patient or his /her relative was willing to participate in the study and to provide a written informed consent<.
Exclusion criteria
Exclusion criteria: 1) Multi-mode imaging assessment suggests there is large vessel occlusion (internal carotid or middle cerebral artery M1 segment), and patients needs interventional thrombectomy; 2) Pre-stroke mRS >= 2; 3) Intracranial hemorrhage confirmed by cranial CT or MRI; 4) A recent (within 30-day) surgery or trauma, or other active or recent serious systemic hemorrhage; or intraspinal surgery and biopsy of substantial organs; 5) pregnant or lactating women; 6) Allergic to tirofiban and contrast agents; 7) Participating in other clinical trials; 8) Systolic blood pressure > 185mmHg or diastolic blood pressure > 110mmHg, and poor control of antihypertensive drugs; 9) There is an arterial puncture in the site where it is not easy to compress the hemostasis within one week; 10) There are large surgical operations or severe trauma in the past 2 weeks; 11) History of myocardial infarction in the past 3 months; 12) A history of major brain trauma or stroke in the past 3 months; 13) Those with a history of hemorrhagic retinopathy; 14) Chronic hemodialysis and severe renal insufficiency (or recent blood tests suggesting glomerular filtration rate 200mmol/L (2.5mg/dl); 15) A known hereditary or acquired hemorrhagic diathesis, coagulation factor deficiency, or taking oral anticoagulant with INR > 1.7; 5) a serum glucose level <= 50 mg/dl; 16) Platelet count < 100,000/mm3 or Hemoglobin < 70g/dL; 17) The life expectancy of any disease <6 months; 18) Any intracranial hemorrhage detected on CT scan immediately after Alteplase infusion. 19) Expected completion of follow-up; 20) Brain tumors with a placeholder effect.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| modified Rankin scale scores;Incidence of intracranial hemorrhage in 48 hours;90-Day mortality rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| percentage of modified Rankin scale scores (0-1score);percentage of modified Rankin scale scores (0-2score);90 days mRS score improvement;NIHSS score change 24 h, 7d after treatment; | — |
Countries
China
Contacts
Public ContactYongpeng Yu
The Affiliated Weihai Central Hospital of Qingdao University
Outcome results
None listed